Mark is the Vice President of Operations for Gallus Biopharmaceuticals. Following 15 years in pharmaceutical and biotechnology process development, Mark transitioned into the operations side of the business where he took on roles of increasing responsibility with Wyeth and Johnson & Johnson. His 18 years in operations have included leadership in every aspect of plant operation, coupled with an exemplary compliance and regulatory record in a commercially licensed facility, the transfer of molecules, building and qualification of new facilities and operational excellence deployment. Gallus specializes in both perfusion and fed batch manufacturing, utilizing flexible stainless steel and disposable bioreactor technologies. At Gallus, a Contract Manufacturing Organization, Mark leads the development, clinical and commercial functions for the concurrent manufacture of multiple clients API.